Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2013

View Archived Issues

Merck & Co. provides pipeline overview in 2012 financial results

BTK inhibitors designed at Novartis

Novartis presents novel HDAC4 inhibitors

Novel platinum complexes developed by Chinese team

Cangene acquires rights to IB-1001

GSK supports AllTrials campaign

Mitsubishi Tanabe's in-house and out-licensed programs advance in third quarter of fiscal 2012

Oncotype DX Colon Cancer test can affect treatment recommendations and costs

Therapeutic cervical cancer vaccine eradicates established tumors in mice

Diagnostics for cancer developed by group of French researchers

The University of Bath designs agents for drug and alcohol abuse

Merck & Co. describes new Trk-A inhibitors

Ability Pharmaceuticals receives grant to develop lipid analogue therapeutic

Summit and Children's National Medical Center form biomarker collaboration for DMD

Autophagy-inducing peptide drug displays antiviral activity

GSK to advance GSK-2586184 into phase II studies

Regen BioPharma files IND for drug-refractory aplastic anemia therapeutic

Phase II trial investigates PC-SOD for idiopathic pulmonary fibrosis in Korea

Seikagaku begins phase II trial for SI-613 in Japan

Biogen acquires full rights to Tysabri

Astellas Pharma profiles pipeline progress of third quarter of fiscal 2012

Seattle Genetics begins two phase I trials of SGN-CD19A

First patient treated in phase I trial of GL-ONC1

Phase II study of Zybrestat plus Avastin passes interim toxicity analysis

Chugai seeks expanded Japanese approval for Herceptin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...